8254 Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices 

prescription opioids, with rates of 

deaths involving prescription opioids 

more than quadrupling from 1999 to 

2019. In response, a range of clinical 

practice guidelines, policies, and 

regulations have been released in recent 

years to address the opioid overdose 

epidemic, with the goals of supporting 

safer opioid prescribing, improving 

diagnosis and treatment of OUD, and 

reducing overdose deaths in the United 

States. 

To design this evaluation, we 

previously conducted and completed a 

‘‘Feasibility Assessment of Health 

Systems’’ via surveys to determine the 

range of policies and guidelines being 

implemented by health systems, 

followed by an ‘‘evaluability 

assessment’’ by means of interviews 

with leaders of nine health systems. For 

the purposes of this evaluation, 

‘‘Chronic pain management policies/ 

guidelines’’ refers to policies/guidelines 

that may include prescribing of opioid 

medications, nonpharmacologic 

therapies, and/or non-opioid 

medications for chronic pain, as well as 

OUD assessment and treatment. 

In early 2020, CDC requested OMB 

approval for a Feasibility Assessment of 

Health Systems (‘‘Feedback on the use 

of the CDC Guideline for Prescribing 

Opioids for Chronic Pain’’) through the 

‘‘Generic Clearance for the Collection of 

Routine Customer Feedback’’ (OMB 

Control No. 0920–1050). This brief 

eligibility assessment consisting of 

surveys was sent to approximately 250 

health systems to understand the 

landscape of health systems and the 

types of guidelines or policies 

implemented, and what strategies were 

used to do so. Of 250 health systems 

contacted, 46 responded and were 

considered for the following 

preliminary phase, the evaluability 

assessment. Among the 46 health 

systems who completed the feasibility 

assessment surveys, nine were selected 

for a more in-depth ‘‘evaluability 

assessment’’ based on several factors 

identified in the initial feasibility 

(survey) assessment, as well as other 

expert knowledge of potential systems. 

The purpose of this data collection 

effort is to: (1) Obtain an enhanced 

understanding of facilitators and 

barriers to guideline-concordant 

management of chronic pain and opioid 

prescribing (including access to MOUD) 

at the health system level, in order to 

improve patient outcomes while 

maximizing patient safety and to 

facilitate uptake by clinicians and 

health systems, (2) describe unintended 

benefits and consequences to guideline/ 

policy implementation, and (3) identify 

racial and ethnic disparities in 

guideline/policy implementation. 

This mixed-methods, pre-post 

evaluation of health systems’ 

implementation of chronic pain 

management and opioid prescribing 

policies/guidelines and the resultant 

outcomes requires both primary data 

collection (such as surveys, key 

informant interviews, focus groups, etc.) 

and secondary data collection (such as 

administrative, EHR, pharmacy 

dispensing, prescribing data, etc.) efforts 

to adequately answer the research 

questions. While secondary data (QI 

measures) from health system EHRs will 

provide longitudinal pre-post measures, 

primary data is needed to understand 

the characteristics and mechanisms of 

practice and patient change that can be 

attributed to the policies and guidelines. 

CDC requests OMB approval for an 

estimated 577 annual burden hours. 

There are no direct costs to respondents 

other than their time to participate in 

the study. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Patient ............................................................................................................ Patient Survey ................................... 667 1 10/60 

Treatment facility staff (Including primary care clinicians, health system 

leaders, and other system staff and representatives).

Clinician Survey ................................

Invitation/Follow up Email .................

1,313 

1,980 

1 

2 

10/60 

3/60 

System Leaders Interview Guide ...... 17 1 1 

Case Study ....................................... 30 1 30/60 

Member Checking Sessions ............. 17 1 1 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–03076 Filed 2–11–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60–Day–22–1283; Docket No. CDC–2022– 

0019] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Monitoring and Reporting for the 

Overdose Data to Action Co-Operative 

Agreement. Information collected will 

provide crucial data for program 

performance monitoring, budget 

tracking, and where applicable, program 

success for programs funded under 

Overdose Data to Action (CDC–RFA– 

CE19–1904). 

DATES: CDC must receive written 

comments on or before April 15, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0019 by either of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices 8255 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Monitoring and Reporting for the 

Overdose Data to Action Co-Operative 

Agreement—Revision—National Center 

for Injury Prevention and Control 

(NCIPC), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC), National Center for 

Injury Prevention and Control (NCIPC) 

seeks OMB approval for a Revision of a 

previously approved Information 

Collection Request (ICR) (OMB Control 

No. 0920–1283, Expiration 01/31/2023) 

for a one-year period, to continue 

collecting information from 

jurisdictions (which include states, 

Washington DC, U.S. Territories, cities 

and counties) funded under the 

Overdose Data to Action (CDC–RFA– 

CE19–1904) funding opportunity. 

Drug overdose deaths in the United 

States increased by 18% per year from 

2014 to 2016. Opioid overdose deaths 

have increased fivefold from 1999 to 

2016, and in 2017, there were more than 

47,000 deaths attributed to opioids. 

While the opioid overdose epidemic 

worsens in scope and magnitude, it is 

also becoming more complex. The 

complex and changing nature of the 

opioid overdose epidemic highlights the 

need for an interdisciplinary, 

comprehensive, and cohesive public 

health approach. 

The purpose of the Overdose Data to 

Action (CDC–RFA–CE19–1904) notice 

of funding opportunity (OD2A NOFO), 

is to support funded jurisdictions in 

obtaining high quality, complete, and 

timely data on opioid prescribing and 

overdoses, and to use those data to 

inform prevention and response efforts. 

There are two required components of 

this award—a surveillance component 

and a prevention component, with 10 

strategies in the funding opportunity 

across both components. The intent is to 

ensure that funded jurisdictions are well 

equipped to do rigorous work under 

both components, and to ensure that 

these components are linked and 

implemented as part of a system. 

This ICR will focus on three tools that 

funded jurisdictions will be required to 

use to assess performance as well as 

measure effectiveness: The Activity 

Progress Report, the Evaluation and 

Performance Measuring Plan, and the 

Organizational Capacity Assessment 

Tool. These tools support the overall 

OD2A NOFO (all strategies above). 

There is an overall reduction in burden 

of 880 burden hours from the previously 

approved request. 

A total of 79 jurisdictions were 

eligible to receive awards under this 

funding opportunity, and 67 

jurisdictions submitted applications, of 

which 66 were funded. Each funded 

jurisdiction will be required to report 

the four elements of this ICR. Reporting 

is based on both web-based tools and 

Word templates. This information is 

being collected to provide crucial data 

to CDC for program monitoring and 

budget tracking, to improve timely CDCrecipient communications, and to 

inform technical assistance and 

guidance documents produced by CDC 

to support program implementation 

among funded jurisdictions. The 

information feedback loop created by 

these information collection tools is 

designed to help jurisdictions decrease 

fatal and nonfatal overdoses. It will also 

provide CDC with the capacity to 

respond in a timely manner to requests 

for information about the program from 

the Department of Health and Human 

Services (HHS), the White House, 

Congress, and other sources. 

CDC requests approval for an 

estimated 462 annual burden hours. 

There is no cost to respondents other 

than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Overdose Data to Action funded jurisdictions (State, territories, counties and cities) and their Designated Delegates.Evaluation and Performance Measuring Plan Template —Annual reporting.

Organizational Capacity Assessment—Annual Reporting.

66 

66 

1 

1 

4 

1 

264 

66 

Activity Progress Report Tool—Annual Reporting.66 1 2 132 

Total ........................................... ........................................................... ........................ ........................ ........................ 462 


jspears on DSK121TN23PROD with NOTICES1
8256 Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–03081 Filed 2–11–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Board of Scientific 

Counselors, National Institute for 

Occupational Safety and Health (BSC, 

NIOSH) 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) is seeking 

nominations for membership on the 

BSC, NIOSH. The BSC NIOSH consists 

of 15 experts in fields associated with 

occupational safety and health, such as 

occupational medicine, occupational 

nursing, industrial hygiene, 

occupational safety, engineering, 

toxicology, chemistry, safety and health 

education, ergonomics, epidemiology, 

biostatistics, psychology, wellness, 

research translation, and evaluation. 

DATES: Nominations for membership on 

the BSC, NIOSH must be received no 

later than April 15, 2022. Packages 

received after this time will not be 

considered for the current membership 

cycle. 

ADDRESSES: All nominations should be 

mailed to NIOSH Docket 278, c/o 

Pauline Benjamin, Committee 

Management Specialist, National 

Institute for Occupational Safety and 

Health, Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

V–24–4, Atlanta, Georgia 30329–4027, 

or emailed (recommended) to 

nioshdocket@cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Emily J.K. Novicki, M.A., M.P.H., 

NIOSH, CDC, 1600 Clifton Road NE, MS 

V24–4, Atlanta, GA, 30329–4027, 

Telephone: (404) 498–2581, or email at 

ENovicki@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Nominations are being sought for 

indviduals who have the expertise and 

qualifications necessary to contribute to 

the accomplishments of the Board’s 

objectives. Nominees will be selected 

based on expertise in the fields 

associated with occupational safety and 

health, such as occupational medicine, 

occupational nursing, industrial 

hygiene, occupational safety, 

engineering, toxicology, chemistry, 

safety and health education, 

ergonomics, epidemiology, biostatistics, 

psychology, wellness, research 

translation, and evaluation. Federal 

employees will not be considered for 

membership. Members may be invited 

to serve for up to four-year terms. 

Selection of members is based on 

candidates’ qualifications to contribute 

to the accomplishment of NIOSH BSC 

objectives https://www.cdc.gov/niosh/ 

bsc/default.html. 

The U.S. Department of Health and 

Human Services policy stipulates that 

committee membership be balanced in 

terms of points of view represented, and 

the committee’s function. Appointments 

shall be made without discrimination 

on the basis of age, race, ethnicity, 

gender, sexual orientation, gender 

identity, HIV status, disability, and 

cultural, religious, or socioeconomic 

status. Nominees must be U.S. citizens, 

and cannot be full-time employees of 

the U.S. Government. Current 

participation on federal workgroups or 

prior experience serving on a federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. Committee 

members are Special Government 

Employees (SGEs), requiring the filing 

of financial disclosure reports at the 

beginning and annually during their 

terms. CDC reviews potential candidates 

for BSC, NIOSH membership each year 

and provides a slate of nominees for 

consideration to the Secretary of HHS 

for final selection. HHS notifies selected 

candidates of their appointment near 

the start of the term in January 2023, or 

as soon as the HHS selection process is 

completed. Note that the need for 

different expertise varies from year to 

year and a candidate who is not selected 

in one year may be reconsidered in a 

subsequent year. SGE nominees must be 

U.S. citizens, and cannot be full-time 

employees of the U.S. Government. 

Candidates should submit the 

following items: 

D Current curriculum vitae, including 

complete contact information 

(telephone numbers, mailing address, 

email address) 

D At least one letter of 

recommendation from person(s) not 

employed by the U.S. Department of 

Health and Human Services. 

(Candidates may submit letter(s) from 

current HHS employees if they wish, 

but at least one letter must be submitted 

by a person not employed by an HHS 

agency (e.g., CDC, NIH, FDA, etc.). 

Nominations may be submitted by the 

candidate him- or herself, or by the 

person/organization recommending the 

candidate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–03037 Filed 2–11–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Healthcare Infection Control Practices 

Advisory Committee (HICPAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Healthcare Infection Control 

Practices Advisory Committee 

(HICPAC). This virtual meeting is open 

to the public, limited only by audio and 

web conference lines (300 audio and 

web conference lines are available). 

Registration is required. To register for 

this web conference, please go to: 

www.cdc.gov/hicpac. All registered 

participants will receive the meeting 

link and instructions shortly before the 

meeting. 

DATES: The meeting will be held on 

March 24, 2022, from 12:00 p.m. to 2:30 

p.m., EDT. 

ADDRESSES: Please click the link below 

to join the webinar: https://

cdc.zoomgov.com/j/1609325835?

pwd=M2Nqa0VMSExYS1RCUj

RKeTVvTzFnZz09. 

Meeting ID: 160 932 5835. 

Passcode: b#B0i6q. 

Dial-in Lines: 

+1–669–254–5252 (San Jose) 

+1–646–828–7666 (New York) 

Meeting ID: 160 932 5835. 

Phone Passcode: 45841052. 

FOR FURTHER INFORMATION CONTACT: 

Sydnee Byrd, M.P.A., HICPAC, Division 

of Healthcare Quality Promotion, 


jspears on DSK121TN23PROD with NOTICES1